Erratum : Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants : Eye (2015), 29, (1173-1180)) doi: 10.1038/eye.2015.98);Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants

Eye (Basingstoke)

Volumn 29, Issue 9, 2015, Pages 1173-1180

  Yang, Y ^a   Bailey, C ^b   Holz, F G ^c   Eter, N ^d   Weber, M ^e   Baker, C ^f   Kiss, S ^g   Menchini, U ^h   Ruiz Moreno, J M ⁱ   Dugel, P ^j   Lotery, A ^k  

^a ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f Paducah Retinal Center   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^j RETINAL CONSULTANTS OF ARIZONA   (United States)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; DELAYED RELEASE FORMULATION; DRUG IMPLANT; GLUCOCORTICOID;

ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CAPSULOTOMY; CATARACT EXTRACTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA EDEMA; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; FOLLOW UP; HUMAN; INTRAVITREAL IMPLANT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; TREATMENT OUTCOME; VISUAL ACUITY; WOUND DEHISCENCE; ADMINISTRATION AND DOSAGE; ADULT; AGED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETIC RETINOPATHY; DRUG IMPLANT; FEMALE; MACULAR EDEMA; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PSEUDOPHAKIA; VISUAL ACUITY;

EID: 84941210435     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.145     Document Type: Erratum

References (33)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-1474.
2. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998-1003.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1-32.
4. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-Term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
5. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312-2318.
6. Mitchell P, RESTORE extension study group. 2-year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): an interim analysis of the Restore Extension Study. Presented at 2012 ARVO Annual Meeting; 6-9 May 2012; Fort Lauderdale, FL (poster 4667).
7. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
8. Boyer DS, Sy J, Chen Rundle A, Hopkins JJ, Erlich JS RISE and RIDE Research Group. Ranibizumab (anti-VEGF) for vision loss due to diabetic macular edema-results of two phase III randomized trials. Presented at American Diabetes Association 71st Scientific Sessions; 24-28 June 2011; San Diego, CA (abstract 0132-LBOR).
9. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
10. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009; 116: 2175-2181 e1.
11. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972-979.
12. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-2254.
13. Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 2012; 130: 1153-1161.
14. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843-1851.
15. Boyer DS, MEAD Study Group. Phase 3, multicenter, masked, randomized, sham-controlled trials to assess the safety and efficacy of 700 μg and 350 μg dexamethasone posterior segment drug delivery system (DEX PS DDS®) in the treatment of patients with diabetic macular edema (DME). Presented at American Academy of Ophthalmology Annual Meeting; 16-19 November 2013; New Orleans, LA.
16. Boyer DS, Yoon YH, Belfort Jr. R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914.
17. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-Term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: e2.
18. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132.
19. ILUVIEN [summary of product characteristics]. Hampshire, UK: Alimera Sciences Limited, 2013.
20. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449 1449.e1-e10.
21. Menchini U, Cappelli S, Virgili G. Cataract surgery and diabetic retinopathy. Semin Ophthalmol 2003; 18: 103-108.
22. Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Arch Ophthalmol 2000; 118: 912-917.
23. Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, et al. Results after lens extraction in patients with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report Number 25. Arch Ophthalmol 1999; 117: 1600-1606.
24. Dowler JG, Sehmi KS, Hykin PG, Hamilton AM. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999; 106: 663-668.
25. Zaczek A, Olivestedt G, Zetterstrom C. Visual outcome after phacoemulsification and IOL implantation in diabetic patients. Br J Ophthalmol 1999; 83: 1036-1041.
26. Dowler JG, Hykin PG, Lightman SL, Hamilton AM. Visual acuity following extracapsular cataract extraction in diabetes: a meta-Analysis. Eye (Lond) 1995; 9: 313-317.
27. Diabetic Retinopathy Clinical Research Network Authors/ Writing Committee, Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S, et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol 2013; 131: 870-879.
28. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806.
29. National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). September 2013. Available from http://www.nice.org.uk/guidance/ta301/resources/ diabetic-macular-oedema-fluocinolone-Acetonideintravitreal-implant-rapid-review-of-Ta271-final-Appraisaldetermination-document2 (accessed 31 October 2014).
30. Antcliff RJ, Poulson A, Flanagan DW. Phacoemulsification in diabetics. Eye (Lond) 1996; 10: 737-741.
31. Sadiq SA, Sleep T, Amoaku WM. The visual results and changes in retinopathy in diabetic patients following cataract surgery. Eur J Ophthalmol 1999; 9: 14-20.
32. Pollack A, Leiba H, Bukelman A, Oliver M. Cystoid macular oedema following cataract extraction in patients with diabetes. Br J Ophthalmol 1992; 76: 221-224.
33. Funatsu H, Yamashita H, Noma H, Shimizu E, Mimura T, Hori S. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg 2002; 28: 1355.